Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection

Table 1 Characteristics of the 309 enrolled patients with gastric cancer

Characteristics		n (%)	Median	Range
Age (yr)			60	29-82
Sex	Male	77 (24.9)
	Female	232 (75.1)
Tumor location	Upper	11 (3.6)
	Middle	134 (43.4)
	Lower	158 (51.1)
	Multiple	6 (1.9)
Operation type	Subtotal gastrectomy	139 (45.0)
	Total gastrectomy	170 (55.0)
Pathology	PAC/TAC	200 (64.7)
	PDAC	74 (23.9)
	SRC/MAC	35 (11.3)
Lauren classification	Intestinal	137 (44.3)
	Non-intestinal	172 (55.7)
T stage	T1	183 (59.2)
	T2	57 (18.4)
	T3	41 (13.3)
	T4	28 (9.1)
Lymph node metastasis	Absence	212 (68.6)
	Presence	97 (31.4)
Tumor size (cm)			3.0	0.5-17.0
Tumor involvement of resection margin	Negative	302 (97.7)
	Positive	7 (2.3)
Adjuvant chemotherapy	No	220 (71.2)
	Yes	89 (28.8)
White blood cell (× 1012 cells/L)			6.87	3.09-20.13
Hemoglobin (g/dL)			13.6	4.1-17.3
NLR			1.96	0.13-22.80
PLR			126.05	2.93-557.13
Albumin (g/dL)			4.3	2.5-5.4
CRP (mg/dL)			1.61	0.0-115.05
FDG uptake	Negative	153 (49.5)
	Positive	156 (50.5)
Tmax1			4.71	2.62-37.80
BM SUV			1.45	0.55-2.66
BLR			0.70	0.28-1.35

¹Measured only in 156 patients with positive FDG uptake. PAC: Papillary adenocarcinoma; TAC: Tubular adenocarcinoma; PDAC: Poorly-differentiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MAC: Mucinous adenocarcinoma; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; FDG: F-18 fluorodexoyglucose; PET/CT: Positron emission tomography/computed tomography; BM: Bone marrow; BLR: BM-to-liver uptake ratio.